GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
Summary
GSK is investing £400 million in a new research and development center in Cambridge, moving many scientists from its Stevenage site. The company plans to increase its late-stage drug trials and cut £1.9 billion in annual costs by 2029, while aiming for revenue of over £40 billion by 2031.Key Facts
- GSK will spend £400 million to open a new research center in Cambridge.
- The Stevenage facility will close, and most scientists will move to Cambridge.
- Cambridge is a major life sciences hub with universities, hospitals, and biotech companies.
- GSK plans to start late-stage trials for at least 20 potential medicines this year, up from 10.
- The company recently bought US cancer specialist Nuvalent for nearly £8 billion.
- GSK aims to cut £1.9 billion in annual costs by 2029 through efficiency measures.
- Patent expiration on the HIV drug dolutegravir (about 20% of sales) in 2028-30 is a concern.
- GSK expects stable or improving profit margins despite patent challenges and is targeting £40 billion+ revenue by 2031.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
